ThursdayJul 25, 2024 1:36 pm

QualityStocksNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Revolutionary Rapid Detoxification Drink Spotlighted in 24/7 Market News Report

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information. The report, which highlights functional beverage market developments, discusses FSD Pharma’s revolutionary rapid detoxification drink, unbuzzd(TM). The drink helps to rapidly restore mental alertness post-alcohol consumption. To read the full news report, visit https://ibn.fm/9qlBY To view the full press release, visit https://ibn.fm/FCJ7S About FSD Pharma Inc. FSD is a biopharmaceutical company dedicated to…

Continue Reading

ThursdayJul 25, 2024 1:00 pm

QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Significant Advancements Following Cargo Management Group Acquisition

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today provided key updates following its acquisition of Cargo Management Group (“CMG”). The acquisition was completed in June and has been instrumental in developing GTVH’s four-pillar model and setting the stage for future growth within the organization. According to the company, the formation of LE Logistic LLC, a wholly owned subsidiary of GTVH, marked a major milestone in its journey towards future growth. This entity is expected to take full charge of the company’s logistics operations once the motor carrier (“MC”) authority from CMG is fully transferred and can be integrated.…

Continue Reading

ThursdayJul 25, 2024 12:25 pm

QualityStocksNewsBreaks – Lucid Group Inc. (NASDAQ: LCID) Inks Nonbinding Supply Agreement with American Producer of High-Grade Anode Materials

Lucid Group (NASDAQ: LCID), maker of the world's most-advanced electric vehicles, has entered into a nonbinding supply agreement with Graphite One Inc.(TSX.V: GPH) (OTCQX: GPHOF). The agreement is for anode active materials (“AAM”). According to the announcement, the agreement, which is initially for five years, is for 5,000 tpa once Graphite One commences production of synthetic graphite. Sales will be based on an agreed price formula tied to future market pricing that also acknowledges base-case pricing. Graphite One officials noted that the agreement helps the company develop its 100% U.S. domestic supply chain. “We are committed to accelerating the transition…

Continue Reading

ThursdayJul 25, 2024 9:45 am

Nightfood Holdings Inc. (NGTF) Eyes Growth with CarryOut Acquisition

Nightfood made its name in the sleep-friendly snack market, but has made two acquisitions diversifying operations recently to capitalize on an emerging market and a reemerging company Nightfood signed an LOI to acquire SWC Group, d/b/a Carryoutsupplies.com Carryoutsupplies.com has serviced over 7,000 wholesale accounts since inception in 2004, but faced extreme challenges in the face of the global covid pandemic Business is returning, presenting an opportunity for Nightfood to grow sales that reached $2 million in 2023 Nightfood Holdings (OTCQB: NGTF) is at it again. The Tarrytown, NY-based company built its name with sleep-friendly snacks and is now starting to…

Continue Reading

ThursdayJul 25, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis On June 27th, PaxMedica will have a Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework The outcomes of this FDA meeting are crucial, representing a key moment for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101 The global ASD therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, driven by increasing…

Continue Reading

WednesdayJul 24, 2024 12:21 pm

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives PO from European Distributor for 29 Mullen GOs

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for 29 Mullen GOS from one of its newest European distribution partners. The order for the GOs, which are Mullen’s commercial micro-urban-delivery vehicle, came from GAMA, which is a distribution partner covering southeast Europe, including the Balkans Region. The order from GAMA, which is valued at $304,000, is part of a previously announced 53-unit commercial vehicle order; that order is for urban delivery vehicles as well as Mullen One and Mullen Three commercial EV cargo vans and trucks, which have not yet been delivered. The compact design…

Continue Reading

WednesdayJul 24, 2024 11:43 am

QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), American West Metals Release Update for Storm Project Drilling, Exploration

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), a publicly traded mineral exploration company exploring for high-grade copper and gold deposits in Virginia and Nunavut, Canada, along with its joint venture partner American West Metals Limited, is reporting on the status of drilling and exploration activities currently underway at the Storm Copper Project. The project is located on Somerset Island, Nunavut, and is being conducted by American West Metals Limited, which has formed a 20/80 unincorporated joint venture with Aston Bay on the project. Highlights of the update indicate that the excellent productivity for the 2024 summer drilling program is…

Continue Reading

WednesdayJul 24, 2024 11:23 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. “We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder,…

Continue Reading

WednesdayJul 24, 2024 9:45 am

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) – Offering Sustainable and Humane Solution to NYC’s Rat Problem

New York City has received lots of backlash, mainly from People for the Ethical Treatment of Animals (“PETA”), for its approach to addressing its rat problem Its approach, so far, has been characterized by the use of traps, poisons, and its “Trash Revolution” program, all of which have been unsustainable SenesTech, a rodent fertility control product provider, through its flagship Evolve(TM) product, offers an alternative that could potentially eliminate the entire rodent population in 12 to 18 months This solution avoids the adverse effects of the use of poisons, both to humans and other animals, and offers a sustainable, more…

Continue Reading

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered